Skip to content

Supernus Pharmaceuticals

US · SUPN #2636 by market cap Listed 1970
28.61 +0.26 +0.92%
Periodic snapshot; not a real-time feed. · 2026-11-20 16:48

Price chart

Pre-market 28.41 +0.21%
After-hours 28.00 -2.13%
50.4426.1628.612026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on SUPN?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -37.9% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has fallen to 7.9% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 6 of 6 factors. Missing data is not a zero score.

Overall D+
ValuationGrowthProfitMomentumHealthAnalyst
Valuation F

How expensive the stock is versus earnings, sales and its own 5-year history.

Forward P/E 80.3x Better than 4%
Price / Sales 7.1x Better than 15%
Growth C

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 2.5% Better than 37%
Net income CAGR (3Y) 11.4% Better than 62%
Free cash flow CAGR (3Y) -26.6% Better than 14%
Profitability C

How much profit the business keeps from each dollar of sales and capital.

Gross margin 89.6% Better than 96%
Operating margin -5.1% Better than 17%
Net margin -5.4% Better than 19%
Return on equity -3.7% Better than 24%
Return on invested capital -4.5% Better than 22%
Momentum C-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -37.6% Better than 12%
6-month return -40.7% Better than 12%
12-month return (ex latest month) -7.2% Better than 25%
Distance below 52-week high 13.9% Better than 74%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 1.9x Better than 53%
Debt to assets 2.8% Better than 85%
Interest coverage 2.1x Better than 38%
Free cash flow / net income 231.8% Better than 81%
Analyst View A-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 83.3% Better than 63%
Upside to average target 83.9% Better than 79%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -3.73%
1M -30.61%
3M -39.70%
6M -41.24%
YTD -42.43%
1Y -36.12%
3Y +4.76%
5Y -14.52%

Key statistics

Price & volume

Prev close
28.35
Open
28.39
Day range
28.15 - 29.51
Avg price
28.86
Volume
2.83M
Turnover
81.70M
Amplitude
4.80%
52-week range
21.48 - 33.22

Valuation

P/E
-42.07
P/E (TTM)
-37.64
P/B
5.59
EPS
-0.68
Net profit
-141.25M
Net assets
1.06B

Share structure

Market cap
5.94B
Float cap
5.78B
Shares out
207.72M
Float shares
201.93M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 61% of range
21.48 33.22

13.9% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+16.79M net over the window

Short interest

Shares short
4.62M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Supernus Pharmaceuticals (SUPN)?

Supernus Pharmaceuticals last traded at 28.61. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Supernus Pharmaceuticals's market cap?

About 5.94B.

What is the P/E ratio of Supernus Pharmaceuticals?

The trailing twelve-month P/E is -37.64, below its own 5-year average of 84.23 — toward the bottom of its historical range (19.86% percentile). See the Valuation tab for the full history.

Does Supernus Pharmaceuticals pay a dividend?

Supernus Pharmaceuticals does not currently pay a regular dividend.

Is Supernus Pharmaceuticals a buy according to analysts?

The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 52.60, which implies 83.9% upside from the current price. This is not investment advice.

What is Supernus Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Supernus Pharmaceuticals a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 16:48:01 · For reference only, not investment advice and not tailored to your situation.

Supernus Pharmaceuticals discussion 0 comments

Add a comment